Review
e) quantitative assessment of VS surveillance as one of the primary study end-points f ) mean follow-up of at least 3 years g) studies in which the reported data included patients with neurofibromatosis type 2, and if these data could not be separately identified from the reported data for patients with VS, were excluded h) the frequency of magnetic resonance imaging (MRI) follow-up must be mentioned in the Materials and methods section with preferably the presentation of a protocol of conservative management
The initial search yielded 163 articles, but 134 articles that did not meet one or more of these inclusion criteria were excluded. Only 29 articles of which the methodology was reviewed and scored using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system remained.
INTRODUCTION
A conservative treatment strategy is often proposed as a primary treatment option in the management of VS. This can be justified because the growth rate of VSs is known to be extremely variable, with most tumors remaining stable or showing only minimal growth for several years. Today, this option is widely adopted in small-or medium-sized tumors or tumors without contact with the brainstem. Because it is impossible to predict the expected behavior of an individual VS based on the information available at diagnosis (age, sex, tumor laterality, and tumor size at presentation), tumor growth rate must be established by means of radiological surveillance, and the imaging interval cannot be guided by [2] then annually If growth every 6 months
Fayad et al. [3] 2014 Retrospective study 114 "Serial" 57.6 (SD=43) 62% 31% Low Weak
Nikopoulos et al. [4] 2013 [6] retrospective studies study proposal Yearly for 5 years Followed up by MRI every other year for 4 years Followed up by MRI 5 years later then stop
Moffat et al. [7] 2012 Prospective study 381 Every 6 months, 50.4 (6-204) 67% NM Low Weak annually for the next 3 years, every 2 years for 6 years, then every 3 years Breivik et al. [8] 2012 Prospective study 186 6 months, 1, 2 46 (9-115) 60% 40% (9% surgery, Moderate Weak and 5 years 31% radiotherapy)
Kaltoft et al. [9] 2011 Retrospective study 959 6 mo, annually 61 73% 17% Low Weak
Hughes et al. [10] 2011 [11] Agrawal et al. [12] 2010 [13] 254% radiotherapy) the baseline data. Only tumor growth rate during the first years of follow-up is predictive of further growth during the upcoming years. Protocols for wait and scan have been proposed in the literature and are based on data from the observation of the natural history of VSs in cohorts of patients usually followed up annually over a prolonged period.
EVIDENCE
The reviewed literature was studied to find an answer to how often should VS be screened for growth. This review comprised 2 meta-analyses, 4 prospective cohort studies, and 23 retrospective case series. A total of 8711 patients were included in these studies. The mean number of patients who were included for the clinical series was 215 (50-2500).
Most studies were initially designed to study the growth rate of VS and found a decreasing percentage of growing tumors along the observation time.
The wait and scan policy had to be changed into an active management in 23% of the cases (range: 7%-62%), and surgery was adopted in 14% and radiotherapy in 9% of the cases.
Although the overall quality of the previous studies is low, all point in the same direction, suggesting a significant reduction of new growing tumors during longer observation times. Following the GRADE system, 24 articles were considered to have a "low" level of evidence for being observational studies. Two meta-analyses and 3 good quality obser- Martin et al. [15] 2009 Retrospective study 276 6months, 43 73% 8% surgery, Low Weak 1 year, 1 year, 11% radiotherapy 2 years, 5 years lifelong Verma et al. [16] 2009 Retrospective study 72 6m,1y, annually 121 60% 40% Low Weak and subsequently every 2-3 y
Ferri et al. [17] 2008 Cohort prospective 123 6mo, 6mo, 57.4 (6-182) 64% 13% surgery, Low Weak study annually 7% radiotherapy, 2% lost to follow-up Nedzelski et al. [18] 2008 Retrospective study 50 Every 6 months, 41.7 (7-152) 51% 22% surgery, Low Weak few years, then 2% radiotherapy annually Hajioff et al. [19] 2008 Retrospective study 72 6 months, 121 (89-271) 60% 35% 11% surgery, Low Weak 6 months, every 19% radiotherapy 1-2 years Martin et al. [20] 2008 Retrospective study 167 Annually for 62 65% 11% surgery, Low Weak 5 years, then 11% radiotherapy every 5 years Stangerup et al. [21] 2006 Raut et al. [26] 2004 Case series prospective 72 6 months, annually 80(52-242) 59.3% 32% Low Weak
Perry et al. [27] 2001 Retrospective study 41 Annually 42 (6-108) 79% surgery Low Weak Rosenberg [28] 2000 Retrospective study 80 Annually 57,6 6-206 42% 7.5% Low Weak
Shin et al. [29] 2000 Retrospective study 87 Every 1-2 years 31 (4-120) 62% 12% 6% surgery, Low Weak 6% radiotherapy NA: not applicable; NM: not mentioned; Y: year; MO: month; GRADE: grading of recommendations, assessment, development, and evaluation vational studies were graded as "moderate" evidence. None of the studies achieved a grade with strength of recommendation better than weak.
CONCLUSION
The quality of evidence and strength of recommendation remains low despite the abundance of studies in this field. This may be explained by methodological issues in the clinical research of such a delicate problem as VS.
1. Nevertheless, most studies arrive at similar conclusions: 2. In order to screen for rapidly-growing tumors, one may perform a first control 6 months after the initial diagnosis. 3. Annual controls were performed for research purposes and were pursued by most authors. 4. If tumor growth occurs, this will most likely happen within the first years after diagnosis. 5. After 5 years, further growth of a tumor that remained stable for years becomes unlikely but may still occur. A lifelong surveillance is, therefore, advised but with tapered, longer intervals. 6. Too regular initial MRI controls may give a false sense of security to patients and discourage them to repeat MRI over a lifelong period. Reducing the number of follow-up scans should have a positive effect on follow-up reliability and health care expenses. 7. A protocol should be easy to use and easy to remember by the health care providers and by the patients.
Remarks
Most of the available evidence of VS growth and proposed protocols come from retrospective case series. The definition of growth varied from 1 mm to >2 mm per year. The follow-up period was quite heterogeneous and usually too short in comparison with the life expectancy of most patients with VS.
Position of EAONO
• Distinguishing individual patients whose tumors will grow and pose a threat to them from those whose tumors will likely remain stable or even regress is central to the current management of patients with VS. • Since most lesions do not grow, a wait and scan strategy seems justified in several patients. • Evidence of tumor growth has become the defining criterion for intervention, especially for small-and medium-sized tumors. • When to discharge a patient from a regime of interval scanning remains uncertain, some evidence indicates that most tumor growth occurs in the first 5 years after identification. However, this is not always the case because cases with late growth after prolonged tumor quiescence have been reported. • Clinicians should seek to instigate national tumor registries in their countries and common data set to facilitate international cooperation. • For the present, the EAONO proposes a protocol mainly based on the Danish experience. Only one additional 6 months repeat MRI after the initial diagnosis could be added to find for fast-growing tumors and a five yearly repeat MRI in the long run. 
